Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709783 | 0.82 | KMT2A (0.43) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL5725289 | 0.79 | POLB (0.46) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL6552892 | 0.79 | MAPT (0.55) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL375957 | 0.78 | KMT2A (0.56) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL70575 | 0.78 | KMT2A (0.56) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL157777 | 0.78 | HPGD (0.70) | KMT2ANPC1MEN1CYP1A2HPGD | |
| SCHEMBL4956852 | 0.77 | NPC1 (0.63) | KMT2ANPC1MEN1NPSR1PPARG | |
| SCHEMBL507698 | 0.77 | — | — | |
| SCHEMBL6432535 | 0.76 | KMT2A (0.54) | KMT2ANPC1MEN1CYP1A2NPSR1 | |
| SCHEMBL159806 | 0.76 | KMT2A (0.56) | KMT2ANPC1MEN1CYP1A2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4617273-A1 | FUSED TRICYCLIC PARP1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4574816-A1 | HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-06-25 | — | — | EP | disclosed |
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| EP-4308573-B1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHROEDINGER INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119948029-A | Fused tricyclic PARP1 inhibitor, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119546582-A | Heterocyclic compound capable of inhibiting PRMT5.MTA and application thereof | 西藏海思科制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119371425-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998042347-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A PHOSPHORYLAMIDE AND AN AYNTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-01 | — | — | WO | disclosed |
| EP-0852498-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011705-A1 | PHOSPHORYLAMIDES, THEIR PREPARATION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5405964-A | Angiotensin antagonist | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-04-11 | — | — | US | disclosed |
| US-4720503-A | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors | MERCK & CO., INC. (US) | 1988-01-19 | — | — | US | disclosed |
| US-4720503-A | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors | MERCK & CO., INC. (US) | 1988-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | KMT2A 526/4885NPC1 3450/4885MEN1 2905/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | KMT2A 2148/4885NPC1 2829/4885MEN1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.